China丨Maxunitech acquired Shijie, became the tops in Sulfentrazone, Flumioxazin technical production capacity

Recently, Maxunitech acquired parts of the original sharehoders’ share of Inner Mongolia Shijie Chemical with its own funds to control this company.

Founded in 2018 and located in Alxa League Economic and Technological Development Zone, Inner Mongolia, Shijie is a manufacturing enterprise integrating the research, development, production and sales of pesticides and fine chemicals. And Shijie also has production lines of Sulfentrazone, Flumioxazin and several chemical intermediates, and has land bank for several new projects.

Maxunitech lnc, which was established in 2000, is a multinational enterprise engaged in plant protection, water ecological restoration and reconstruction, environmental engineering. Maxunitech lnc already has the production capacity of Sulfentrazone and Flumioxazin. However, after holding the shares of Shijie Chemical, Maxunitech lnc will jump to the forefront in the world with the total annual production capacity of 4,000 tons of Sulfentrazone and 3,000 tons of Flumioxazin.

Dr Huang, the general manager of Maxunitech, expressed that the company has conducted product registration and market layout in North America, South America, Australia, China and other major agrochemical markets around soybeans, sugarcane, cotton, wheat and other crops and non-agricultural markets in North America and China, creating a product portfolio for specific markets and crops to meet the needs of customers and farmers.

Now Maxunitech has three production bases of technicals and one of formulations after taking control the Shijie chemical, which means the production layout is more reasonable. The new production capacity of Sulfentrazone and Flumioxazin, including the complete supply chain’s integration of key intermediates, has effectively improved the company’s product supply capacity, supply stability and cost competitiveness. All these further expanded Maxunitech’s influence in the global market. In the future, Maxunitech will continue to make great efforts in R&D, registration, production and supply, as soon as possible to promote the production of Pinoxaden, Prothioconazole, Saflufenacil and other products and projects with independent intellectual property rights, to provide more and better products and services for new and old customers around the world.